The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade (Q34288025)

1 August 2017

The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade (English)

1 reference

1 August 2017

0 references

1

Antoni Ribas

1 reference

1 August 2017

Paul C Tumeh

2

1 reference

PubMed ID

24970841

1 August 2017

language of work or name

English

0 references

publication date

26 June 2014

1 reference

1 August 2017

Clinical Cancer Research

1 reference

1 August 2017

20

1 reference

1 August 2017

19

1 reference

1 August 2017

4982-4984

1 reference

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184978

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184978

Digital genomic quantification of tumor-infiltrating lymphocytes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184978

Nivolumab plus ipilimumab in advanced melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184978

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184978

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184978

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184978

Tumor Immunotherapy Directed at PD-1

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184978

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184978

The blockade of immune checkpoints in cancer immunotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184978

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4184978

10.1158/1078-0432.CCR-14-0933

6 July 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

PubMed ID

24970841